Affimed GmbH

163 articles about Affimed GmbH

• Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

  11/14/2023

  Affimed N.V. reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.

• Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

  11/9/2023

  Affimed N.V. announced that the International Nonproprietary Names Expert Committee of the World Health Organization has selected "acimtamig" for the nonproprietary name of the Company’s investigational drug for CD30-positive Lymphomas, previously known as AFM13.

• Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

  11/7/2023

  Affimed N.V. announced that it will release third quarter 2023 results and corporate update on Tuesday, November 14, 2023.

• Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

  11/2/2023

  Affimed N.V. announced two upcoming presentations on its lead innate cell engager AFM13 at the American Society of Hematology 2023 Annual Meeting.

• Affimed to Participate in Upcoming November 2023 Investor Conferences

  11/1/2023

  Affimed N.V. announced that the Company’s management will participate in the following investor conferences during the month of November 2023.

• Affimed Announces Listing Transfer to Nasdaq Capital Markets - October 04, 2023

  10/4/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it has received approval from the Listing Qualifications Department of the Nasdaq Stock Market to transfer the listing of its shares from the Nasdaq Global Market to the Nasdaq Capital Market.

• Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

  9/27/2023

  Affimed N.V. announced that an abstract with a comparison of NK cell redirected by the Company’s innate cell engagers versus CAR-NK cells has been accepted for poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, which will be held on November 1-5, 2023 in San Diego, California.

• Affimed to Present at the Cantor Global Healthcare Conference 2023

  9/21/2023

  Affimed N.V. announced that its Chief Financial Officer, Angus Smith, will participate in a fireside chat at the Cantor Global Healthcare Conference 2023 on Thursday, September 28, 2023 at 1:15 p.m. Eastern Daylight Time / 19:15 Central European Time.

• Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

  9/12/2023

  Affimed N.V. announced that the FDA has granted fast track designation to the combination of its innate cell engager AFM13 with AlloNK® for the potential treatment of relapsed/refractory Hodgkin lymphoma.

• Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

  9/7/2023

  Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 11:00 a.m. Eastern Daylight Time / 17:00 Central European Time.

• Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

  8/22/2023

  Affimed N.V. announced the publication of a manuscript that demonstrates how the FcRn-pH-HPLC technology can be leveraged to predict PK properties of various ICE® formats built on the ROCK® platform.

• Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

  8/10/2023

  Affimed N.V. reported financial results and provided an update on clinical and corporate progress for the second quarter of 2023.

• Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023

  8/3/2023

  Affimed N.V. announced that it will release second quarter 2023 results and corporate update on Thursday, August 10, 2023.

• Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

  6/22/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board.

• Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

  6/9/2023

  Affimed N.V. announced that two abstracts have been accepted for presentation at the 17th International Conference on Malignant Lymphoma taking place in Lugano, Switzerland on June 13-17, 2023.

• Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan

  6/3/2023

  Affimed N.V. announced the presentation at the American Society of Clinical Oncology Annual Meeting of safety and efficacy data from the EGFR mutant NSCLC expansion cohort of its ongoing phase 1/2 study investigating innate cell engager AFM24 as monotherapy.

• Affimed to Present at the 2023 Jefferies Healthcare Conference

  5/30/2023

  Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. Eastern Daylight Time / 14:30 Central European Time.

• Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology

  5/25/2023

  Affimed N.V. announced the publication of two abstracts with its innate cell engager AFM24 in advance of the American Society of Clinical Oncology Annual Meeting, taking place on June 2 - 6, 2023 in Chicago, IL.

• Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress

  5/23/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results and provided an update on clinical and corporate progress for the first quarter of 2023.

• Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

  5/23/2023

  Affimed N.V. announced that the U.S. Food and Drug Administration has cleared its IND application for the combination of AFM13, its first-in-class tetravalent bispecific innate cell engager and AB-101, Artiva Biotherapeutics Inc.’s clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived natural killer cells to initiate the clinical trial, AFM13-203.